---
title: "Key facts: GSK signs $1B deal for RNA therapies; completes buyback of 2.2M shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276809378.md"
description: "GSK has signed a licensing deal with Frontier Biotechnologies worth up to $1 billion for two RNA therapies for kidney diseases, including a $40 million upfront payment.12On February 24, 2026, GSK plc bought 2,229,000 shares in its buyback program, totaling 242,120,094 treasury shares, or 5.94% of voting rights from 4,074,032,332 issued.3"
datetime: "2026-02-25T01:03:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276809378.md)
  - [en](https://longbridge.com/en/news/276809378.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276809378.md)
---

# Key facts: GSK signs $1B deal for RNA therapies; completes buyback of 2.2M shares

-   GSK has signed a licensing deal with Frontier Biotechnologies worth up to $1 billion for two RNA therapies for kidney diseases, including a $40 million upfront payment.12
-   On February 24, 2026, GSK plc bought 2,229,000 shares in its buyback program, totaling 242,120,094 treasury shares, or 5.94% of voting rights from 4,074,032,332 issued.3

### Related Stocks

- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [560600.CN](https://longbridge.com/en/quote/560600.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [688221.CN](https://longbridge.com/en/quote/688221.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [588860.CN](https://longbridge.com/en/quote/588860.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [516820.CN](https://longbridge.com/en/quote/516820.CN.md)
- [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [513700.CN](https://longbridge.com/en/quote/513700.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)

## Related News & Research

- [GSK: Japan's MHLW Expands Eligible Population For Arexvy](https://longbridge.com/en/news/286723820.md)
- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)
- [HBM Holdings Says Director Probed by CSRC, Sees No Impact on Operations](https://longbridge.com/en/news/286197909.md)
- [<![CDATA[GSK Enters Exclusive Collaboration with SBP Group to Accelerate Bepirovirsen at Launch in Mainland China ]]>](https://longbridge.com/en/news/285955820.md)
- [Leads Biolabs R&D Symposium: Platform Synergy and Multi-Mechanism Integration Reshape the Immuno-Oncology Landscape](https://longbridge.com/en/news/285930281.md)